Harnessing the tumor microenvironment: Targeted cancer therapies through modulation of epithelial-mesenchymal transition Review
| Authors: | Glaviano, A.; Lau, H. S. H.; Carter, L. M.; Lee, E. H. C.; Lam, H. Y.; Okina, E.; Tan, D. J. J.; Tan, W.; Ang, H. L.; Carbone, D.; Yee, M. Y. H.; Shanmugam, M. K.; Huang, X. Z.; Sethi, G.; Tan, T. Z.; Lim, L. H. K.; Huang, R. Y. J.; Ungefroren, H.; Giovannetti, E.; Tang, D. G.; Bruno, T. C.; Luo, P.; Andersen, M. H.; Qian, B. Z.; Ishihara, J.; Radisky, D. C.; Elias, S.; Yadav, S.; Kim, M.; Robert, C.; Diana, P.; Schalper, K. A.; Shi, T.; Merghoub, T.; Krebs, S.; Kusumbe, A. P.; Davids, M. S.; Brown, J. R.; Kumar, A. P. |
| Review Title: | Harnessing the tumor microenvironment: Targeted cancer therapies through modulation of epithelial-mesenchymal transition |
| Abstract: | The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, and signaling molecules that interact to promote tumor growth and therapeutic resistance. Elucidating the intricate interactions between cancer cells and the TME is crucial in understanding cancer progression and therapeutic challenges. A critical process induced by TME signaling is the epithelial-mesenchymal transition (EMT), wherein epithelial cells acquire mesenchymal traits, which enhance their motility and invasiveness and promote metastasis and cancer progression. By targeting various components of the TME, novel investigational strategies aim to disrupt the TME's contribution to the EMT, thereby improving treatment efficacy, addressing therapeutic resistance, and offering a nuanced approach to cancer therapy. This review scrutinizes the key players in the TME and the TME's contribution to the EMT, emphasizing avenues to therapeutically disrupt the interactions between the various TME components. Moreover, the article discusses the TME's implications for resistance mechanisms and highlights the current therapeutic strategies toward TME modulation along with potential caveats. © 2025. The Author(s). |
| Keywords: | signal transduction; neoplasm; neoplasms; animal; animals; metastasis; drug effect; drug resistance; pathology; drug resistance, neoplasm; drug therapy; therapy; theranostics; epithelial-mesenchymal transition; tumor microenvironment; molecularly targeted therapy; epithelial mesenchymal transition; molecular targeted therapy; procedures; cancer; humans; human; extracellular matrix (ecm); myeloid-derived suppressor cells (mdscs); tumor microenvironment (tme); cancer-associated fibroblasts (cafs); chimeric antigen-receptor (car) t-cell therapy; dendritic cells (dcs); epithelial-mesenchymal transition (emt); natural killer (nk) cells; t-cell receptor (tcr) therapy; t-cells, b-cells, tumor-associated macrophages (tams); tumor-associated neutrophils (tans) |
| Journal Title: | Journal of Hematology & Oncology |
| Volume: | 18 |
| ISSN: | 1756-8722 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2025-01-13 |
| Start Page: | 6 |
| Language: | English |
| DOI: | 10.1186/s13045-024-01634-6 |
| PUBMED: | 39806516 |
| PROVIDER: | scopus |
| PMCID: | PMC11733683 |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work